The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- COVID-19
- Sars Cov 2
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04854759
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Konrad Rejdak, Professor, PhD, MD Independent Public Clinical Hospital No. 4 in Lublin
Get Well Soon